Welcome to exalt
Enabling personalized cancer treatments
We are committed to personalizing cancer treatments by functional precision medicine.
Meetings
25-27 September, 2024, Copenhagen, Denmark
EHA-SFPM PRECISION MEDICINE MEETING
Prof. Philipp Staber, MD, PhD, Tea Pemovska, PhD
and Alexander Pichler, MD
European Hematology Association
Featured
'Staber and his team are now recruiting patients into a second prospective study in patients with hematological cancer, EXALT-2, which is comparing the utility of genomic screening, single-cell functional precision medicine and physicians’ choice in guiding therapy selection. "Here, we’re investigating three decision-making strategies. We’re not investigating the drugs,” he says. Roche, of Basel, Switzerland, is collaborating on the study, which is employing its FoundationOne Heme test to provide genomic profiles of patients’ cancers.'
'All eyes are therefore on Staber and his randomized trial, which researchers anticipate will go a long way towards convincing clinicians that genomics is not the be-all and end-all of personalized care. "Paradigm shifts can be very threatening to people," says Howard, the University of Mississippi radiologist, 'but it shouldn’t be threatening. It’s just another tool in our arsenal against disease." '
EXALT clinical trials
EXALT-2 trial NCT04470947 recruiting
Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
Cancer Discovery 1 February 2022
C. Kornauth, T. Pemovska, G. I. Vademir et al. Giulio Superti-Furga, Berend Snijder, Philipp B. Staber
Awards
Falling Walls Berlin 9 November 2022
exalt was invited to the Falling Walls Berlin
AIT TEC: FWL Austria & Summer School on Entrepreneurship (v.l.: Alexander Pichler und Hermann Hauser, austrian entrepreneur, venture capitalist and inventor ) © Lorenz Seidler